Sellas Life Sciences Group Inc (SLS.OQ)
SLS.OQ on NASDAQ Stock Exchange Capital Market
4.94USD
23 Apr 2018
4.94USD
23 Apr 2018
Change (% chg)
$-0.44 (-8.18%)
$-0.44 (-8.18%)
Prev Close
$5.38
$5.38
Open
$5.40
$5.40
Day's High
$5.41
$5.41
Day's Low
$4.81
$4.81
Volume
27,960
27,960
Avg. Vol
80,893
80,893
52-wk High
$19.74
$19.74
52-wk Low
$3.43
$3.43
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Angelos Stergiou |
2017 | President, Chief Executive Officer, Director | |
Gene Mack |
2018 | Chief Financial Officer, Treasurer | |
Nicholas Sarlis |
2017 | Chief Medical Officer, Senior Vice President | |
Gregory Torre |
2017 | Chief Regulatory Officer, Senior Vice President | |
John Burns |
2017 | Vice President - Finance, Corporate Controller |
- BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
- BRIEF-Sellas Life Sciences Group Files For Non-Timely 10 K With U.S. SEC
- BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin
- BRIEF-Sellas Life Sciences Announces Notice Of Allowance From U.S. Patent And Trademark Office
- BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement